Alopecia Areata in India: Symptoms, Causes & Treatment | aihealz
DermatologymoderateICD-10 · L66.9
Alopecia Areata.Care & specialists in India
In India, alopecia Areata is managed by dermatologists. Alopecia is the medical term for hair loss and covers a family of distinct conditions ranging from common androgenetic (male- or female-pattern) thinning to autoimmune alopecia areata, stress-driven telogen effluvium, and scarring inflammatory disorders. Roughly half of men show visible hair loss by age 50 and 40% of women by age 50, while alopecia areata affects about 2% of people at some point in life with peak onset under age 30.
Alopecia (ICD-10: L63, L64, L65, L66) is a broad term for partial or complete loss of hair from areas where it normally grows. Clinically and biologically the condition is split into non-scarring alopecia, in which the follicular ostia and stem cells remain intact and regrowth is biologically possible, and scarring (cicatricial) alopecia, in which the follicle is destroyed and replaced by fibrosis, making regrowth impossible. Within non-scarring alopecia, androgenetic alopecia (L64) reflects genetically programmed follicular miniaturization driven by dihydrotestosterone in androgen-sensitive scalp regions; alopecia areata (L63) is a T-cell-mediated autoimmune attack on the anagen hair bulb; telogen effluvium (L65.0) is a synchronized shift of follicles into the resting telogen phase triggered by a systemic stressor (illness, childbirth, surgery, weight loss, thyroid dysfunction, drugs); anagen effluvium (L65.1) is loss of actively growing hairs from chemotherapy, radiation, or toxin exposure. Scarring alopecias are subdivided by histology into lymphocytic (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia, discoid lupus erythematosus), neutrophilic (folliculitis decalvans, dissecting cellulitis), and mixed forms.
key facts
Prevalence
Androgenetic alopecia affects approximately 50% of men by age 50 and 40% of women by age 50; alopecia areata lifetime prevalence around 2%
Demographics
All ethnicities affected; central centrifugal cicatricial alopecia disproportionately affects Black women; frontal fibrosing alopecia rising in postmenopausal women
Avg. age
Androgenetic alopecia typically begins age 20-40; alopecia areata onset most commonly under 30; telogen effluvium any age
Global cases
Hair loss is one of the top dermatology consultations worldwide; the global hair-care and hair-loss treatment market exceeded USD 8 billion in 2023
Specialist
Dermatology
ICD-10
L66.9
§ 02
How you might notice it
The key symptoms of Alopecia Areata are: Gradual recession of the frontal hairline at the temples and progressive thinning over the crown in men — the classic Hamilton-Norwood male-pattern progression spanning 10-30 years., Diffuse widening of the central parting and reduced ponytail volume without true bitemporal recession in women — the Ludwig female-pattern presentation., Sudden appearance of one or more well-circumscribed coin-shaped patches of complete hair loss with preserved follicular openings and characteristic exclamation-mark hairs at the patch border — alopecia areata., Diffuse heavy shedding (100-300 hairs daily for weeks, particularly noticeable on the shower drain or pillow) starting 2-4 months after a triggering illness, childbirth, surgery, weight loss, or stress — telogen effluvium., Rapid global hair loss within 1-3 weeks of chemotherapy initiation — anagen effluvium., Progressive recession of the frontal and temporal hairline with thinning of the eyebrows and visible perifollicular erythema in postmenopausal women — frontal fibrosing alopecia., Painful, itchy, or burning scalp with red, scaly, or pustular patches of hair loss and loss of follicular ostia visible on dermoscopy — scarring alopecia..
01Gradual recession of the frontal hairline at the temples and progressive thinning over the crown in men — the classic Hamilton-Norwood male-pattern progression spanning 10-30 years.
02Diffuse widening of the central parting and reduced ponytail volume without true bitemporal recession in women — the Ludwig female-pattern presentation.
03Sudden appearance of one or more well-circumscribed coin-shaped patches of complete hair loss with preserved follicular openings and characteristic exclamation-mark hairs at the patch border — alopecia areata.
§ 03
How it’s diagnosed
diagnosis
Diagnosis starts with a focused history (onset, distribution, shedding versus thinning, triggers, family history, hair-care practices, drugs, comorbidities) and visual assessment of the scalp pattern. The clinician compares regions and looks for preserved or lost follicular ostia — the single most important sign separating non-scarring from scarring alopecia. A hair-pull test (gently extracting 30-60 hairs from three scalp regions) helps quantify active shedding: more than 6 telogen hairs per pull is abnormal. Trichoscopy (handheld polarized dermoscopy of the scalp) is now considered standard and demonstrates pattern-specific features: hair shaft diameter variation and miniaturization in androgenetic alopecia, exclamation-mark hairs and yellow dots in alopecia areata, perifollicular erythema and absent follicular ostia in scarring alopecia. Targeted laboratory testing includes complete blood count, ferritin (target above 70 ng/mL), TSH, vitamin D, and zinc; ANA, ENA, and androgen panels are added when systemic or hormonal disease is suspected. A 4 mm punch biopsy of the active edge — read by a dermatopathologist trained in horizontal sectioning — is the diagnostic standard for scarring alopecia and any presentation that cannot be classified clinically. Photography for serial comparison and validated severity scales (Sinclair score for female-pattern, SALT score for alopecia areata) anchor follow-up assessment.
Key tests
01
Trichoscopy (dermoscopy of the scalp)Visualizes hair shaft variability, miniaturization, exclamation-mark hairs, yellow and black dots, perifollicular signs, and presence or absence of follicular ostia
02
Hair-pull testQuantifies active shedding by counting hairs extracted with gentle traction
03
Scalp punch biopsy (4 mm, horizontal sectioning)Diagnostic standard for scarring alopecia and unclassified cases; differentiates non-scarring from scarring and identifies specific subtype
§ 04
Treatment & cost
medical treatments
✓Minoxidil 5% topical (twice daily) or 5% foam (once daily)
✓Oral minoxidil 0.625-5 mg daily
✓Finasteride 1 mg orally daily (men)
✓Spironolactone 100-200 mg orally daily (women)
surgical options
Follicular-unit excision (FUE) hair transplantationGraft survival 85-95% at 12 months in experienced hands; visible cosmetic improvement in over 90% of well-selected patients
Follicular-unit transplantation (FUT, strip excision)Graft survival 90-95%; total hair recovery typically requires 1-3 sessions
Scalp reduction or flap surgeryUseful for selected reconstruction cases; high satisfaction in carefully selected individuals
Eyebrow and beard transplantationGraft survival 70-85%; aesthetic outcome dependent on operator skill
§ 05
Causes & risk factors
known causes
Genetic susceptibility to androgens (androgenetic alopecia)
Polygenic inheritance — over 200 risk loci identified, with the AR gene on the X chromosome carrying the largest effect. In affected follicles, type II 5-alpha-reductase converts testosterone to dihydrotestosterone, which binds androgen receptors and progressively miniaturizes follicles over years.
Autoimmune T-cell attack on the hair follicle (alopecia areata)
CD8+ T cells and natural killer cells infiltrate the anagen hair bulb and disrupt the immune-privilege normally protective of growing follicles. Strong associations with HLA-DQB1 alleles and shared susceptibility with vitiligo, autoimmune thyroid disease, type 1 diabetes, and atopic conditions.
Systemic stressor synchronizing follicles into telogen (telogen effluvium)
Major physiological or psychological stressors push a substantial fraction of anagen follicles into the resting telogen phase simultaneously; mass shedding occurs 2-4 months later when those follicles are pushed out by the next anagen cycle. Triggers include febrile illness, childbirth, major surgery, rapid weight loss, iron and zinc deficiency, thyroid dysfunction, and severe emotional stress.
Drugs and medical treatments
Cytotoxic chemotherapy and head radiation cause anagen effluvium. Many other drugs cause telogen effluvium: retinoids, ACE inhibitors, beta-blockers, anticoagulants, anticonvulsants, antithyroid agents, isotretinoin, lithium, and hormonal contraceptive changes. Effect appears 2-4 months after initiation or dose change and resolves after withdrawal.
Mechanical hair tension and physical trauma (traction alopecia)
Sustained tension on the hair shaft from tight braiding, weaves, ponytails, religious turbans, or helmet use. Causes early follicular damage that is reversible if traction is released; chronic traction over years produces scarring around hair follicles.
Primary scalp inflammation and fibrosis (scarring alopecias)
§ 06
Living with it
01Avoid sustained tight hair tension (braids, weaves, ponytails worn the same way daily, religious turbans without padding) and rotate styles to reduce traction injury.
02Use sulfate-free shampoos and avoid frequent chemical processing (relaxers, perms) in those prone to scarring alopecia.
03Treat dandruff and seborrheic dermatitis early to limit scalp inflammation that exacerbates shedding.
04Maintain ferritin above 70 ng/mL, vitamin D above 30 ng/mL, and a euthyroid state to support normal hair cycling.
05Discuss hair-related side-effects before starting drugs known to provoke telogen effluvium (retinoids, anticoagulants, anticonvulsants, ACE inhibitors).
recommended foods
•Iron-rich foods (lean red meat, liver, lentils, dark leafy greens) with vitamin C to support ferritin
•Adequate protein intake (1-1.2 g/kg/day) to support keratin synthesis
•Omega-3-rich foods (salmon, sardines, flaxseed) with documented anti-inflammatory benefit on scalp
•
§ 07
When to seek help
why see a dermatology
A dermatologist confirms the precise alopecia subtype with trichoscopy and, when indicated, scalp biopsy; identifies treatable systemic contributors; and selects evidence-based therapy tailored to subtype and severity. Specialist referral is essential before invasive treatments such as hair transplantation, which fails if applied to ongoing autoimmune or scarring disease.
01Permanent follicular loss and irreversible scarring if scarring alopecia is diagnosed late.
02Psychological morbidity — depression, anxiety, social withdrawal, and reduced quality of life are commonly reported in moderate-to-severe alopecia; consider mental-health support early.
03Scalp dermatitis, allergic contact dermatitis to minoxidil, or contact dermatitis to immunotherapy treatments.
04Drug-related side-effects (sexual dysfunction with finasteride, hyperkalemia or breast tenderness with spironolactone, infections and lipid changes with JAK inhibitors).
05Donor-area scarring or visible thinning following high-density hair transplantation when donor capacity is overestimated.
Androgenetic alopecia (male-pattern and female-pattern hair loss)Progressive miniaturization of follicles in androgen-sensitive scalp regions. In men: bitemporal recession and crown thinning (Hamilton-Norwood pattern). In women: diffuse thinning over the crown with preservation of the frontal hairline (Ludwig pattern). Cumulative effect of genetic susceptibility and dihydrotestosterone.
Alopecia areata (patchy, totalis, universalis)Autoimmune T-cell attack on anagen hair bulbs. Presents as discrete round or oval patches of complete hair loss with preserved follicular ostia and characteristic exclamation-mark hairs at the edge. Severe forms: alopecia totalis (whole scalp), alopecia universalis (whole body), and ophiasis (band along occipital and temporal hairline).
Telogen effluviumDiffuse shedding of 100-300 hairs daily, 2-4 months after a triggering event (febrile illness, childbirth, major surgery, rapid weight loss, iron deficiency, thyroid disease, severe psychological stress, or certain drugs). Self-limited; resolves within 6-12 months once the trigger is corrected.
Anagen effluviumLoss of actively growing anagen hairs days to weeks after exposure to a toxic insult — most often cytotoxic chemotherapy, radiation, severe protein malnutrition, or thallium poisoning. Affects 65-100% of the scalp depending on the agent.
Scarring (cicatricial) alopeciaPermanent destruction of follicles by inflammation and fibrosis. Subtypes: lichen planopilaris (perifollicular erythema and scale, scalp pruritus), frontal fibrosing alopecia (band-like recession of frontal hairline with eyebrow loss in postmenopausal women), central centrifugal cicatricial alopecia (crown-centered scarring most common in Black women), discoid lupus erythematosus, folliculitis decalvans, and dissecting cellulitis.
Traction alopeciaMechanical follicle injury from sustained hair tension — tight braids, weaves, extensions, ponytails, religious turban-wearing, helmet use. Initially reversible; chronic traction over years produces scarring.
Living with Alopecia Areata
Timeline
Topical minoxidil: initial shed weeks 4-8, visible improvement months 4-6, plateau by 12 months. Oral finasteride: stabilization by 6 months, visible regrowth by 12 months in responders. JAK inhibitors for alopecia areata: initial regrowth by 12 weeks, maximum effect by 36-52 weeks. Telogen effluvium: resolution within 6-12 months of trigger correction. Hair transplantation: grafted hairs shed by week 4, regrow from month 3-4, final density by month 12-18. Scarring alopecias: stabilization within 6-12 months of effective therapy; existing density not recoverable.
Lifestyle
01Treat scalp pruritus and inflammation early — recurrent itch or pain predicts scarring alopecia activity.
02Apply minoxidil on a dry scalp once or twice daily, exactly as prescribed; expect 4-8 weeks of mild initial shed.
03Photograph the scalp every 3-4 months under standardized lighting for objective comparison.
04Limit heat styling above 175 °C and avoid pulling wet hair tightly.
05Manage stress, sleep, and mental health — recurrent stress is a documented trigger for telogen effluvium and alopecia areata flares.
06Wear sunscreen on bald or thinning scalp areas to prevent ultraviolet damage and reduce skin-cancer risk.
Daily management
01Apply prescribed topical minoxidil on a dry scalp at fixed times.
Complementary approaches
Platelet-rich plasma (PRP) scalp injectionsAutologous PRP injected into scalp at 4-6 week intervals for 3-4 sessions, then maintenance every 3-6 months. Active growth factors stimulate follicular activity and prolong anagen. Meta-analyses show modest but reproducible benefit in androgenetic alopecia.
Low-level laser therapy (LLLT) devicesFDA-cleared red-light combs and helmets used 3 times weekly. Improve hair count by approximately 15-20% in pooled trial data of androgenetic alopecia; effect is gradual over 6-12 months.
Choosing a doctor
Choose a board-certified dermatologist with a specific hair-disorders interest, ideally trained at an academic alopecia clinic and familiar with current JAK-inhibitor protocols. For surgery, look for an ISHRS-affiliated hair-transplant surgeon with documented before-and-after results in your hair type and pattern. Avoid clinics that promise guaranteed regrowth or that recommend transplantation before subtype diagnosis.
Alopecia UK →UK-based charity providing patient support, peer groups, and clinical-trial information for all forms of alopecia.
§ 08
Frequently asked
What is alopecia?▾▴
Alopecia is the medical term for hair loss. It is not a single disease but a family of conditions ranging from common pattern hair loss (androgenetic alopecia) to autoimmune patchy hair loss (alopecia areata), stress-related shedding (telogen effluvium), and scarring inflammatory disorders. Treatment depends on which type is present.
What is the most common cause of hair loss?▾▴
Androgenetic alopecia is by far the most common cause, affecting roughly half of men and 40% of women by age 50. It is a genetically programmed, gradual miniaturization of hair follicles driven by dihydrotestosterone, producing receding hairlines and crown thinning in men and diffuse central thinning in women.
Is alopecia areata an autoimmune disease?▾▴
Yes. Alopecia areata is caused by T cells attacking the hair follicle and disrupting the immune privilege that normally protects growing hairs. It is associated with other autoimmune conditions including vitiligo, autoimmune thyroid disease, and type 1 diabetes, and runs in families in roughly 25% of cases.
Can alopecia be cured?▾▴
Most forms can be effectively treated but not permanently cured. Androgenetic alopecia is stabilized or improved by minoxidil and finasteride or spironolactone in most patients. Alopecia areata can achieve substantial regrowth with JAK inhibitors. Scarring alopecia can be arrested but already destroyed follicles cannot grow back.
How quickly does alopecia treatment work?▾▴
Visible benefit from minoxidil and finasteride typically appears at 4-6 months and plateaus by 12 months. Intralesional steroid injections for alopecia areata patches show regrowth in 4-8 weeks. Oral JAK inhibitors achieve maximum regrowth between weeks 36 and 52. Telogen effluvium recovers within 6-12 months of trigger correction.
What is telogen effluvium?▾▴
Telogen effluvium is a temporary diffuse hair shedding that begins 2-4 months after a major trigger — a febrile illness, childbirth, surgery, sudden weight loss, iron deficiency, thyroid problems, or severe stress. Up to 300 hairs are shed daily. It is self-limited and resolves within 6-12 months once the trigger is corrected.
Is hair loss a normal part of aging?▾▴
Some degree of hair miniaturization is universal with age, but visible hair loss is not inevitable. Androgenetic alopecia is the major driver, with cumulative prevalence rising in each decade. Lifestyle, hormones, nutrition, and underlying disease all modify the rate; effective treatments exist to slow or reverse progression.
Does stress cause hair loss?▾▴
Severe physical or psychological stress can trigger telogen effluvium, with diffuse shedding starting 2-4 months later. Chronic stress can also flare alopecia areata and worsen androgenetic alopecia. Most stress-related shedding is reversible once the stressor is addressed and underlying contributors (iron, thyroid, sleep) are corrected.
What is finasteride and is it safe?▾▴
Finasteride is an oral medication that blocks the enzyme converting testosterone to dihydrotestosterone, reducing scalp DHT by roughly 60%. It slows progression in 90% of men and produces regrowth in around 65% over 2 years. Sexual side-effects occur in 1-2% and are usually reversible; rare persistent symptoms are reported. Not approved in women of reproductive age.
Does minoxidil really work?▾▴
Yes. Topical and oral minoxidil increase hair count and visible density in roughly 60% of users with androgenetic alopecia within 6-12 months. An initial 4-8 week shedding phase is normal and predicts future response. Effect is maintained only with continued use.
What are JAK inhibitors for alopecia areata?▾▴
JAK inhibitors are oral immunomodulators that block cytokine signaling driving the autoimmune attack on hair follicles. Baricitinib (FDA approved 2022) and ritlecitinib (2023) produce ≥80% scalp regrowth in 35-40% of severe alopecia areata patients within 36-52 weeks and have transformed treatment of the autoimmune form.
Can hair transplants give permanent results?▾▴
Transplanted hairs from the genetically resistant donor area at the back of the scalp retain their resistance to DHT and tend to persist for life. Graft survival is 85-95% at 12 months in skilled hands. Underlying androgenetic alopecia still progresses, so medical therapy is usually continued to preserve native hair around the grafts.
Does PRP work for hair loss?▾▴
Platelet-rich plasma injections produce modest but real improvement in androgenetic alopecia in placebo-controlled trials, with hair count increases of approximately 15-25%. Typical protocol is three or four sessions at 4-6 week intervals followed by 6-month maintenance. Best as an adjunct rather than monotherapy.
Can children get alopecia?▾▴
Yes. Alopecia areata commonly begins in childhood; tinea capitis is the most common cause of patchy hair loss in children. Trichotillomania appears in school-age and adolescent children. Androgenetic alopecia can begin in adolescence in those with strong genetic loading.
What tests should I have for hair loss?▾▴
Standard workup includes complete blood count, ferritin, TSH, vitamin D, and zinc. Women with sudden onset, irregular periods, or signs of hyperandrogenism should add free testosterone, DHEAS, and prolactin. A scalp biopsy is added when scarring alopecia is suspected or when the pattern is unclear after trichoscopy.
Does diet affect hair loss?▾▴
Yes, especially through micronutrient deficiencies. Iron deficiency, low vitamin D, zinc deficiency, and severely restricted diets all worsen shedding. Adequate protein, iron, omega-3, and zinc support normal hair growth. Most supplements offer minimal benefit unless a deficiency is documented; biotin in particular is rarely deficient and can interfere with thyroid testing.
Why is frontal fibrosing alopecia becoming more common?▾▴
Incidence has risen approximately tenfold over the past 20 years, especially in postmenopausal women. The cause is not fully understood but proposed contributors include hormonal changes, leave-on sunscreens, and possibly facial cosmetics. Early diagnosis and combination treatment with hydroxychloroquine and 5-alpha-reductase inhibitors arrest progression in most patients.
Is scarring alopecia reversible?▾▴
No. Once a follicle has been destroyed by inflammatory scarring it cannot regrow. The aim of treatment is to stop further loss; existing density can be improved cosmetically with transplantation only after disease activity has been quiet for at least 1-2 years.
Will my hair grow back after chemotherapy?▾▴
Yes, almost always. Chemotherapy-induced anagen effluvium typically reverses within 3-6 months of completing treatment, with full density returning by 12 months. Texture and color may differ initially. Scalp cooling devices during infusion reduce hair loss in roughly 50% of patients.
Does wearing hats cause baldness?▾▴
No. Hats and helmets do not cause androgenetic alopecia. Very tight hats worn for long hours can contribute to traction alopecia at the hairline in susceptible individuals, but standard hat use is not a cause. Hereditary, hormonal, and autoimmune factors drive most hair loss.
Can hair loss be reversed naturally?▾▴
Reversible causes — telogen effluvium from illness, deficiency, stress, or drug effects — usually recover spontaneously once the trigger is corrected. Androgenetic alopecia does not reverse without active medical treatment. Lifestyle factors (sleep, nutrition, stress management) support medical therapy but do not replace it for genetic or autoimmune forms.
Diffuse heavy shedding (100-300 hairs daily for weeks, particularly noticeable on the shower drain or pillow) starting 2-4 months after a triggering illness, childbirth, surgery, weight loss, or stress — telogen effluvium.
05Rapid global hair loss within 1-3 weeks of chemotherapy initiation — anagen effluvium.
06Progressive recession of the frontal and temporal hairline with thinning of the eyebrows and visible perifollicular erythema in postmenopausal women — frontal fibrosing alopecia.
07Painful, itchy, or burning scalp with red, scaly, or pustular patches of hair loss and loss of follicular ostia visible on dermoscopy — scarring alopecia.
08Crown-centered patches of broken hair, perifollicular hyperpigmentation, and scarring in middle-aged Black women — central centrifugal cicatricial alopecia.
09Patchy hair loss along the hairline or scalp from tight braiding, weaves, or sustained traction — early traction alopecia, with little hairs along the affected border (fringe sign).
10Loss of eyebrows, eyelashes, and body hair in addition to scalp involvement — alopecia universalis or chemotherapy-induced anagen effluvium.
11Visible nail pitting, trachyonychia, or fingernail ridging — present in 10-66% of patients with alopecia areata.
early warning signs
•Increased hair on the pillow, shower drain, or hairbrush over several weeks
•Subtle widening of the central scalp parting noticed when styling hair
•Reduced ponytail circumference compared with the previous year
•Solitary smooth round patch of complete hair loss on the scalp, beard, or eyebrow
•Itchy, burning, or tender scalp accompanied by hair shedding — red flag for scarring alopecia
● emergency signs
•Sudden, painful, ulcerating scalp lesions with rapid hair loss — exclude infection, vasculitis, or cutaneous malignancy
•Rapidly progressive frontal hairline recession with scaling, erythema, or eyebrow loss — likely scarring alopecia requiring biopsy
•Hair loss accompanied by malar rash, joint pain, or sun sensitivity — exclude systemic lupus erythematosus
•Profound shedding with weight loss, palpitations, or temperature intolerance — exclude hyperthyroidism or other endocrine cause
•Patches of hair loss with broken hairs of different lengths in a child or adolescent with anxiety or stress — consider trichotillomania and assess mental-health risk
04
Targeted blood tests (ferritin, TSH, T4, vitamin D, complete blood count, zinc, ANA where indicated)Detects reversible systemic contributors and excludes underlying autoimmune or endocrine disease
05
Androgen panel (free testosterone, DHEAS, prolactin, 17-OH-progesterone) in womenIdentifies hyperandrogenism, polycystic ovary syndrome, or rare adrenal sources of androgens in women with hirsutism, irregular cycles, or sudden hair loss
06
Photographic documentation with standardized lighting and anglesTracks progression and treatment response over months and years
Outlook
Outlook depends on subtype, severity, and treatment timing. Androgenetic alopecia is progressive without treatment; with optimal therapy started early, more than 80% of men halt visible progression and 60-65% achieve cosmetically meaningful regrowth, and similar proportions of women stabilize or improve. Alopecia areata has a more variable course — roughly 30-50% of patchy cases regrow spontaneously within a year, but extensive (≥50% scalp) or long-standing disease has lower spontaneous remission rates and historically poor response to standard treatments; JAK inhibitors have improved outcomes substantially, with 35-40% achieving near-complete regrowth by 36-52 weeks. Telogen effluvium has an excellent prognosis with trigger correction; density returns to baseline within 6-12 months in 90% of cases. Scarring alopecias have the most guarded outlook: areas already destroyed cannot regrow, but timely diagnosis and treatment can arrest progression in 60-75% of patients. Outcomes in central centrifugal cicatricial alopecia and frontal fibrosing alopecia are best when treatment starts in early disease before significant follicular loss. Hair transplantation outcomes are durable in stable androgenetic alopecia (graft survival 85-95% at 1 year), provided ongoing medical therapy is continued to preserve native hair.
Heterogeneous group: lymphocytic-mediated lichen planopilaris and frontal fibrosing alopecia, neutrophil-driven folliculitis decalvans, and mixed forms. Triggers include autoimmune disease, contact sensitizers (sunscreens implicated in frontal fibrosing alopecia), genetic predisposition, and chronic hair-care practices.
Nutritional deficiency and metabolic disease
Iron deficiency, vitamin D insufficiency, zinc deficiency, severe protein malnutrition, biotin deficiency, and uncontrolled thyroid disease all impair anagen and provoke shedding. Effect is largely on telogen effluvium and worsening of androgenetic alopecia rather than a unique alopecia pattern.
risk factors
Family history of pattern hair lossgenetic
First-degree relatives of men with androgenetic alopecia have a 2.5-5× increased risk; concordance in monozygotic twins exceeds 80%. Female-pattern hair loss is also strongly heritable but with lower penetrance.
Agenon-modifiable
Cumulative prevalence of androgenetic alopecia rises steadily across decades: roughly 16% of men aged 18-29 and 53% aged 40-49 show measurable hair loss in epidemiological surveys.
Male sex (androgenetic)non-modifiable
Men reach more advanced stages on average than women because of higher circulating androgens. Female-pattern hair loss accelerates after menopause when estrogen falls and the androgen-to-estrogen ratio rises.
Atopic background and autoimmune family historygenetic
Personal or family history of atopic dermatitis, asthma, vitiligo, thyroid autoimmunity, type 1 diabetes, or alopecia areata raises risk of alopecia areata. Roughly 25% of patients have a positive family history.
Major life stressor in past 6 monthsmodifiable
Febrile illness, childbirth, surgery, bereavement, severe weight loss, or sustained psychological stress are well-established triggers of telogen effluvium and may flare alopecia areata. The shed typically peaks 2-4 months after the trigger.
Chronic hair-care practices with traction or chemical processingmodifiable
Tight braids, weaves, extensions, ponytails, frequent chemical relaxers, and high-heat styling are well-documented contributors to traction alopecia and central centrifugal cicatricial alopecia. Risk is highest in Black women.
Underlying autoimmune or endocrine diseasemodifiable
Thyroid disease, lupus, iron-deficiency anemia, polycystic ovary syndrome, vitamin D insufficiency, and uncontrolled diabetes are routinely associated with shedding and worsening androgenetic alopecia; correcting them often improves hair density.
Zinc-containing foods (oysters, pumpkin seeds, beef) where dietary intake is low
foods to avoid
•Severely restrictive crash diets and very low-calorie regimens, which routinely trigger telogen effluvium
•High-dose vitamin A and isotretinoin without medical supervision, which can provoke effluvium
•High-dose selenium and biotin supplements unless deficient — biotin interferes with thyroid and troponin assays
•Smoking and excessive alcohol, both linked to worsened androgenetic alopecia in cohort studies
01Dermatology consultation with trichoscopy capability
02Dermatopathology service experienced in horizontal scalp sections
03Access to JAK inhibitors and standardized infection screening
04ISHRS-affiliated hair restoration surgery if transplantation is planned
05Onsite endocrinology and rheumatology for systemic contributors
Essential facilities
Dedicated hair and scalp clinics within academic dermatology centresISHRS-accredited hair restoration surgery practicesDermatopathology services with horizontal scalp section expertiseReproductive endocrinology services for women with hyperandrogenismMental-health services for body-image and trichotillomania support
TrichotillomaniaCompulsive hair pulling producing patchy hair loss of variable length and asymmetric shape, distinct from alopecia areata by broken hairs of differing lengths within affected zones. Often coexists with anxiety, depression, or OCD.
02Use a wide-tooth comb and avoid aggressive towel-drying on wet hair.
03Take oral medications (finasteride, spironolactone, baricitinib) with the same daily routine to improve adherence.
04Track shedding in a brief log — date, severity, and any triggers.
05Apply broad-spectrum sunscreen on bald or thinning scalp before outdoor exposure.
06Attend follow-up photography and density check every 4-6 months.
Exercise
Regular moderate aerobic exercise (150 minutes per week) improves stress and metabolic markers that influence shedding. Resistance training does not increase androgenic alopecia risk in men despite older claims about testosterone increases. Wear absorbent headbands rather than tight caps to reduce sweat retention and scalp irritation.